Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS
August 22nd 2025In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.
Watch
CAR T and Bispecifics Pose Different Challenges in Blood Cancer Treatment: Ravi Vij, MD, MBA
August 21st 2025Ravi Vij, MD, MBA, discusses the logistical differences between administering CAR T-cell therapy and bispecific antibodies, and how emerging CAR T technologies could affect patient access.
Watch
Preventive Cardiology Through Fresh Eyes: Highlights From ASPC’s 2025 Congress
August 21st 2025The American Society for Preventive Cardiology (ASPC) marked its 40th anniversary this year at the ASPC Congress on CVD Prevention in Boston, held August 1-3, with 3 days of debates, presentations, oral abstracts, and posters.
Watch
Navigating Perioperative Immunotherapy Decisions in Lung Cancer Care: Jonathan Thompson, MD, MS
August 21st 2025Jonathan Thompson, MD, MS, explains that adjuvant immunotherapy benefits patients with early-stage lung cancer with incomplete neoadjuvant response, while treatment decisions in the adjuvant setting must weigh efficacy, toxicity, and limited evidence.
Watch
Jonathan Thompson, MD, MS, highlighted that reducing delays in molecular testing and treatment initiation is critical for improving lung cancer outcomes, and that clinical trial data suggest immunotherapy duration can often be safely de-escalated in patients who achieve a complete pathologic response.
Watch
Biomarker Testing, Perioperative Treatment in NSCLC: Frank Weinberg, MD, PhD
August 20th 2025A panel held during the Institute for Value-Based Medicine event in Chicago on August 14, 2025, included discussions of access to biomarker testing and perioperative treatment in patients with non–small cell lung cancer (NSCLC).
Watch
Balancing Safety and Access: Renal Denervation in Hypertension With Deepak L. Bhatt, MD, MPH, MBA
August 19th 2025Deepak L. Bhatt, MD, MPH, MBA, of Mount Sinai Fuster Heart Hospital, spoke at the recent ASPC 2025 Congress on CVD Prevention to illustrate both the benefits and risks associated with renal denervation. Bhatt addresses the procedure in the context of lifestyle interventions and novel drug therapies.
Watch
Expanding the Role of NGS and Retesting in Early and Refractory NSCLC: Jonathan Thompson, MD, MS
August 19th 2025Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective retesting at progression can identify resistance mutations or new targets to optimize value-based care.
Watch
Embedding Reflex Biomarker Testing to Advance Precision Lung Cancer Care: Jonathan Thompson, MD, MS
August 18th 2025Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision therapy in lung cancer and to address persistent disparities in timely, equitable access to care.
Watch
Clayton Irvine, PharmD, MBA, MS, discusses how pharmacists are essential to advancing payer–provider collaboration in value-based care by shaping formularies, standardizing drug reviews, leveraging real-world evidence, and leading pilot programs to optimize patient outcomes and cost-effectiveness.
Watch
Pediatric Pharmacists Are Expanding Their Reach in Hospitals and Beyond: Marry Vuong, PharmD, BCPPS
August 16th 2025With growing roles in inpatient care and new telehealth models, pediatric pharmacists are reshaping how and where children receive specialized medication support, explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.
Watch
Clayton Irvine, PharmD, MBA, MS, emphasized that optimizing value-based access to cell and gene therapies requires standardized care protocols, coordinated transitions between care settings, careful evaluation of prior authorization and financial assistance options, and formulary decisions that balance clinical outcomes with both direct and indirect costs to patients and institutions.
Watch
Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD
August 14th 2025Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients and their treatment team and key distinct toxicities that require vigilance.
Watch
Clayton Irvine, PharmD, MBA, MS, discusses strategies to address payer-driven biosimilar and prior authorization challenges through integrated digital solutions, while advocating for flexible, regularly reviewed treatment pathways supported by molecular tumor boards and artificial intelligence to balance standardization with personalized, biomarker-driven oncology care.
Watch
Clayton Irvine, PharmD, MBA, MS, explains that leveraging high-quality, real-world data; cross-institutional collaboration; standardized care pathways; advanced technologies; and integrated academic–community oncology partnerships can improve treatment decision-making, reduce financial toxicity, address drug shortages, and optimize infusion center efficiency.
Watch
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen